Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service

Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service

The detection of bio-marker plays an important role in the diagnosis and understanding of related diseases. CD BioGlyco has a variety of advanced technology platforms and analytical tools to help customers detect glyco-biomarker α1-Antitrypsin (A1AT). We are confident to become your indispensable research assistant in the field of glycoproteomics.


A1AT, also known as α1-protease inhibit (α1-PI), is a glycoprotein synthesized mainly by the liver. It is the most important protease inhibitor in human plasma, accounting for more than 90% of the total plasma protease inhibitory capacity. It can inhibit a variety of serine endopeptidases, such as neutrophil elastase (NE), plasmin, trypsin and thrombin. The main functions of A1AT including protecting normal cells and organs from protease damage, inhibiting infection and inflammation, and maintaining the balance of the body's internal environment.

A1AT deficiency (AATD) is a relatively common but under-recognized genetic disorder. In this disease, aggregation of A1AT glycoproteins leads to their accumulation in hepatocytes, and reduced levels are released into the circulation. When pulmonary A1AT concentrations are low, neutrophil elastase is not neutralized by A1AT and can destroy lung tissue, leading to early-onset emphysema, especially in smokers. Further clinical manifestation of specific mutations of the SERPINA1 gene encoding A1AT is liver disease, manifesting as hepatitis and jaundice in infancy and as cirrhosis in children and adults.

AIAT deficiency  is an inherited disorder affecting mainly the liver and lung. Fig.1 AIAT deficiency is an inherited disorder affecting mainly the liver and lung. (Janciauskiene, 2019)

Our Services

A1AT deficiency is currently detected by protein immunoassay, phenotyping and genotyping for Z and S mutations, but a fully automated method for standard biochemical analyzers is not yet available. Researchers of CD BioGlyco have established a method for automated determination of serum A1AT by measurement of antitryptic activity. Our automated assay involves the determination of serum antitrypsin capacity on an automated analyzer using trypsin and succinylated gelatin as substrates in the existence of trinitrobenzene sulfonic acid. This method is rapid, automated, stable, and could be a useful method for exploring A1AT deficiency, especially in large-scale studies.


  • Diagnosis of AATD
  • Application in inflammatory diseases
  • Diagnosis of juvenile hepatitis, cirrhosis, and hepatocellular carcinoma

Advantages of Us

  • High degree of precision, accuracy, and reproducibility
  • Robust and reproducible data
  • Professional research teams
  • Rigorous scientific attitude

As an expert in the field of glyco-biomarker detection, CD BioGlyco offers a variety of measurement techniques with the advantage of high sensitivity for detecting low abundance A1AT in plasma, serum and other complex matrices. If you need more information, please feel free to contact us.


  1. Janciauskiene, S.M.; et al. The discovery of α1-antitrypsin and its role in health and disease. Respiratory Medicine. 2011, 105(8):1129-1139.
This service is for Research Use Only, not intended for any clinical use.

About Us

CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.

Contact Us

Copyright © CD BioGlyco. All rights reserved.